Celularity Regains Nasdaq Compliance, Cuts $13M Liabilities After 2025 10-K
Celularity filed its 2025 Form 10-K on April 30, 2026, and on May 1 regained compliance with Nasdaq Listing Rule 5250(c)(1). The company out-licensed its biomaterials portfolio, cut liabilities by about $13 million and realigned personnel to focus on its core longevity and cell therapy platforms.
1. Form 10-K Filing and Nasdaq Compliance
Celularity filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, on April 30, 2026, and received confirmation on May 1 that it complied with Nasdaq Listing Rule 5250(c)(1), closing its April 16 non-compliance notification.
2. Strategic Restructuring Measures
To strengthen its balance sheet and streamline operations, the company out-licensed its biomaterials portfolio and transitioned associated employees, realigned non-core personnel including certain executive departures, and reduced recorded liabilities by approximately $13 million.
3. Focus on Core Longevity Platforms
With a leaner cost structure and renewed focus on its core longevity and cell therapy platforms leveraging postpartum placenta biology, Celularity aims to drive long-term growth and deliver transformative regenerative medicine solutions.